Harrow (HROW) Total Non-Current Liabilities (2014 - 2024)
Harrow (HROW) recorded quarterly Total Non-Current Liabilities of $291.2 million in Q3 2024, up 18.5% quarter-over-quarter from $245.7 million in Q2 2024, and up 40.04% on a YoY basis from $208.0 million in Q4 2023.
Harrow (HROW) Total Non-Current Liabilities (2014 - 2024) Analysis & Trends
Harrow's Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $291.2 million for Q3 2024.
- In Q3 2024, Total Non-Current Liabilities rose 40.04% year-over-year to $291.2 million; the TTM figure through Sep 2024 stood at $291.2 million (up 40.04% YoY), while the FY2023 annual figure was $239.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities was $291.2 million for Q3 2024 at Harrow, up from $245.7 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $291.2 million in Q3 2024 to a low of $27.6 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $147.1 million across 4 years, with a median of $196.7 million in 2023.
- The sharpest annual moves came in 2021 and 2024: Total Non-Current Liabilities fell 11.21% in 2021, then soared 40.04% in 2024.
- A 4-year view of Total Non-Current Liabilities shows it stood at $29.8 million in 2020, then decreased by 7.59% to $27.6 million in 2021, then jumped by 766.65% to $239.0 million in 2023, then rose by 21.82% to $291.2 million in 2024.
- The last three Total Non-Current Liabilities figures came in at $291.2 million (Q3 2024), $245.7 million (Q2 2024), and $232.6 million (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 18.28 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 11.64 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 599.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 44.12 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1.24 Bn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.26 Bn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 2.44 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1.81 Bn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1.13 Bn |
| 10 | Harrow | 1.25 Bn | 1.15 Bn | 27.05 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 291.21 Mn |
| Jun 30, 2024 | 245.74 Mn |
| Mar 31, 2024 | 232.62 Mn |
| Dec 31, 2023 | 239.04 Mn |
| Sep 30, 2023 | 207.95 Mn |
| Jun 30, 2023 | 199.66 Mn |
| Mar 31, 2023 | 193.70 Mn |
| Mar 31, 2021 | 27.58 Mn |
| Dec 31, 2020 | 29.85 Mn |
| Sep 30, 2020 | 33.74 Mn |
| Jun 30, 2020 | 33.26 Mn |
| Mar 31, 2020 | 31.07 Mn |
| Dec 31, 2019 | 30.87 Mn |
| Sep 30, 2019 | 30.17 Mn |
| Jun 30, 2019 | 29.36 Mn |
| Mar 31, 2019 | 28.68 Mn |
| Dec 31, 2018 | 23.90 Mn |
| Sep 30, 2018 | 23.04 Mn |
| Jun 30, 2018 | 21.80 Mn |
| Mar 31, 2018 | 20.32 Mn |